Skip to main content
National Donor Day: How To Be the Match With Richa Thakur, MD, and Will Smith
Keira Smith
Expert Analysis
Oncology Data Advisor® · National Donor Day: How To Be the Match With Richa Thakur, MD, and Will Smith On February 14, Oncology Data Advisor is celebrating National Donor Day and recognizing the contributions of individuals who have given organ and tissue donations for patients in need. In this interview, Fellows Forum member Dr. Richa Thakur has a conversation with Will Smith, a High School History Teacher, who gave an anonymous stem cell donation through Be the Match (the National Marrow Donor Program, NMDP) in 2015.  
Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Keira Smith
Expert Analysis
Oncology Data Advisor® · Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward In this interview, Dr. Jason Mouabbi, OncData Editorial Board Member and Breast Medical Oncologist at MD Anderson Cancer Center, speaks with Dr. Ross Maclean and Michael Glover about the debate surrounding accelerated FDA approvals, including...
National Cancer Prevention Month: Rising Trends and How to Combat Them With Samuel Kareff, Matthew Hadfield, Waqas Haque, and Joseph Kalis
Keira Smith
Expert Analysis
Oncology Data Advisor® · National Cancer Prevention Month: Rising Trends and How to Combat Them In honor of National Cancer Prevention Month 2024, members of the Oncology Data Advisor Editorial Board and Fellows Forum sat down for a panel discussion about the rising incidence of cancer diagnoses, factors contributing to them, and how to counsel patients in light of these emerging trends.  
Breaking Developments in Neuroendocrine Tumor Research With Samuel Kareff, MD, MPH, and Aman Chauhan, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Breaking Developments in Neuroendocrine Tumor Research: Dr. Samuel Kareff and Dr. Aman Chauhan In this Fellows Forum interview, Samuel Kareff, MD, MPH, interviews Aman Chauhan, MD, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, about how he became involved in neuroendocrine cancer research, the latest developments in novel therapies, and the future of using radiopharmaceuticals and theranostics to revolutionize the treatment of neuroendocrine tumors.  
World Cancer Day 2024: A Live Panel Discussion
Keira Smith
Expert Analysis
Oncology Data Advisor® · World Cancer Day 2024 with Oncology Data Advisor In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular testing, clinica...
Gallbladder and Bile Duct Cancer Awareness Month: Improving Screening and Treatment Options With Waqas Haque, MD, MPH, and Matthew Hadfield, DO
Keira Smith
Expert Analysis
Oncology Data Advisor® · Gallbladder and Bile Duct Cancer Awareness Month: Improving Screening and Treatment Options In honor of Gallbladder and Bile Duct Cancer Awareness Month this February, Fellows Forum members Dr. Waqas Haque and Dr. Matthew Hadfield sat down for a discussion on the challenges in diagnosis of gallbladder and bile duct cancers and the importance of genetic sequencing for making targeted treatments available for patients.  
National Cancer Prevention Month: Lowering Prostate Cancer Risk With Stephen Freedland, MD, and William Aronson, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · National Cancer Prevention Month With Stephen Freedland and William Aronson In honor of National Cancer Prevention Month, Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, sat down with Dr. William Aronson, Professor of Urology at the University of C...
Racial and Socioeconomic Disparities in the CLL Community Oncology Setting With Ira Zackon, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Racial and Socioeconomic Disparities in the CLL Community Oncology Setting: Ira Zackon, MD At the recent 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ira Zackon, MD, a Senior Medical Director with Ontada, to discuss his abstract and presentation about racial a...
Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study With Sabarish Ayyappan, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study: Sabarish Ayyappan, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Sabarish Ayyappan, MD, the Director of Hematological Malignancies at the City of Hope Cancer Center, to discuss the ELM-2 s...
Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL With Jon Arnason, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL: Jon Arnason, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Jon Arnason, MD, a Lymphoma Clinical Trial Specialist at Beth Israel Deaconess Medical Center, to discuss his abstract and pre...
Guiding Dietary Choices During Multiple Myeloma Treatment With Richa Parikh, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Guiding Dietary Choices During Multiple Myeloma Treatment: Richa Parikh, MD In this interview from the 2023 American Society of Hematology Annual Meeting, Richa Parikh, MD, a third-year Hematology/Oncology Fellow at Karmanos Cancer Institute, discusses her team's study investigating the role of diet in multiple myeloma and how its findings can be used to help guide dietary decisions for patients.  
Highlights of Multiple Myeloma Research Presented at ASH With Urvi Shah, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Highlights of Multiple Myeloma Research Presented at ASH 2023: Urvi Shah, MD At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agents being presented. After listening to the podcast, be sure to watch Dr. Shah's free CME activity or book a live meeting for your institution to hear more expert perspectives on new directions in multiple myeloma treatment!  
Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma With Swetha Kambhampati, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Real-World Outcomes of Brexucabtagene Autoleucel for Mantle Cell Lymphoma: Swetha Kambhampati, MD At the recent American Society of Hematology (ASH) Annual Meeting, Swetha Kambhampati, an Assistant Professor in the Division of Lymphoma at City of Hope, sat down with Oncology Data Advisor to further discuss her pr...
Exploring Revumenib for KMT2-Rearranged Acute Leukemias in the AUGMENT Trial With Ibrahim Aldoss, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Exploring Revumenib for KMT2-Rearranged Acute Leukemias in the AUGMENT Trial: Ibrahim Aldoss, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Ibrahim Aldoss, MD, an Associate Professor in the Department of Hematology and Hematopoietic Cell Transplantati...
Streamlining the Pathology Workflow Through Artificial Intelligence With Waqas Haque, MD, MPH, and Leif Honda of TriMetis
Keira Smith
Expert Analysis
Oncology Data Advisor® · Streamlining the Pathology Workflow Through AI: Waqas Haque and Leif Honda of TriMetis This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.  
Streamlining the Pathology Workflow Through Artificial Intelligence With Waqas Haque, MD, MPH, and Leif Honda of TriMetis
Keira Smith
Expert Analysis
This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.  
Managing Acute Leukemias and Lymphomas When Patients Stay Local With Dipti Patel-Donnelly, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Managing Acute Leukemias and Lymphomas When Patients Stay Local: Dipti Patel-Donnelly, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Dipti Patel-Donnelly, a Medical Oncology at Virginia Cancer Specialists, hosted a session highlighting how to optimize management when patients with hema...
Exploring Acalabrutinib Plus or Minus Obinutuzumab for CLL in the ELEVATE-TN Study With Jeff Sharman, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Exploring Acalabrutinib ± Obinutuzumab for CLL in the ELEVATE-TN Study: Jeff Sharman, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Jeff P. Sharman, the Medical Director of Hematology Research for Sarah Cannon Research Institute and the US Oncology Network, presented the long...
Improving End-of-Life Care for Patients With Acute Myeloid Leukemia Receiving Non-Curative Therapy: Richa Thakur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving End-of-Life Care for Patients With AML Receiving Non-Curative Therapy: Richa Thakur, MD In this interview from the American Society of Hematology (ASH) Annual Meeting, Dr. Richa Thakur, OncData Fellows Forum member and Hematology/Oncology Fellow at Northwell Health, discusses her poster presentation on ...
Improving Quality of Life in Multiple Myeloma Through Bortezomib Dose Reduction With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving QOL in Multiple Myeloma With Bortezomib Dose Reduction: Rahul Banerjee and Gurbakhash Kaur At the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Rahul Banerjee, Editor in Chief of Oncology Data Advisor, sat down with Dr. Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas (UT) Southwestern Medical Center, to discuss their abstract about real-world dosing and prescribing patterns of bortezomib in newly diagnosed multiple myeloma. Dr. Banerjee and Dr. Kaur debate the pros and cons of once- versus twice-weekly dosing of bortezomib, its impact on tolerability and outcomes, and changes in trial design that are needed to make once-weekly dosing a new standard in clinical practice.